Nektar Therapeutics (NKTR) Misses Q1 EPS by 1c, Miss on Revenues

Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.42), $0.01 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $26.8 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c